DermTech, Inc.

OTCPK:DMTK.Q Stok Raporu

Piyasa değeri: US$35.0

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

DermTech Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

DermTech şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-15,374,285.7%

Geri Alım Getirisi

Toplam Hissedar Getirisi-15,374,285.7%
Gelecekteki Temettü Verimin/a
Temettü Büyümesin/a
Bir sonraki temettü ödeme tarihin/a
Eski temettü tarihin/a
Hisse başına temettün/a
Ödeme oranın/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Analiz Makalesi • May 21

DermTech, Inc. (NASDAQ:DMTK) Not Doing Enough For Some Investors As Its Shares Slump 44%

To the annoyance of some shareholders, DermTech, Inc. ( NASDAQ:DMTK ) shares are down a considerable 44% in the last...
Analiz Makalesi • Mar 02

We're A Little Worried About DermTech's (NASDAQ:DMTK) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analiz Makalesi • Mar 02

Investors Don't See Light At End Of DermTech, Inc.'s (NASDAQ:DMTK) Tunnel And Push Stock Down 28%

To the annoyance of some shareholders, DermTech, Inc. ( NASDAQ:DMTK ) shares are down a considerable 28% in the last...
Analiz Makalesi • Dec 28

Revenues Working Against DermTech, Inc.'s (NASDAQ:DMTK) Share Price

You may think that with a price-to-sales (or "P/S") ratio of 4.5x DermTech, Inc. ( NASDAQ:DMTK ) is definitely a stock...
Analiz Makalesi • Sep 18

Companies Like DermTech (NASDAQ:DMTK) Could Be Quite Risky

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analiz Makalesi • Jun 14

Can DermTech (NASDAQ:DMTK) Afford To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analiz Makalesi • May 10

Need To Know: The Consensus Just Cut Its DermTech, Inc. (NASDAQ:DMTK) Estimates For 2023

One thing we could say about the analysts on DermTech, Inc. ( NASDAQ:DMTK ) - they aren't optimistic, having just made...
Analiz Makalesi • May 06

DermTech, Inc. (NASDAQ:DMTK) Not Doing Enough For Some Investors As Its Shares Slump 37%

To the annoyance of some shareholders, DermTech, Inc. ( NASDAQ:DMTK ) shares are down a considerable 37% in the last...
Analiz Makalesi • Jan 16

We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analiz Makalesi • Nov 08

Analyst Forecasts Just Became More Bearish On DermTech, Inc. (NASDAQ:DMTK)

The latest analyst coverage could presage a bad day for DermTech, Inc. ( NASDAQ:DMTK ), with the analysts making...
Analiz Makalesi • Oct 11

Will DermTech (NASDAQ:DMTK) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Oct 11

DermTech grants stock options

DermTech (NASDAQ:DMTK) granted one new, non-executive employee non-qualified stock options to buy ~38.78K common shares. The stock options, which have an exercise price of $4 per share, were granted under Inducement Equity Incentive Plan, the company said in an Oct. 10 press release.
Seeking Alpha • Sep 01

Diving Into DermTech

Summary Today, we take our first look at DermTech, Inc., a small molecular testing concern. The company is seeing some sales traction and the stock sells for less than cash value, but DermTech's cash burn rate is more than concerning. A full investment analysis of DermTech follows in the paragraphs below. Come friends, it's not too late to seek a newer world.”― Alfred Lord Tennyson Today, we put the spotlight on a small diagnostic firm called DermTech, Inc. (DMTK). This company has what it is a potential "best of breed" and non-invasive way to test for melanoma. Its core product is seeing some sales traction and the company currently has a lot of cash on the balance sheet. However, cash burn is a major concern around DermTech. An analysis follows below. Seeking Alpha Company Overview: DermTech, Inc. is a molecular testing concern based out of La Jolla, California. The company develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the U.S. The shares currently trade around $5.50 a share and sport an approximate market capitalization of $170 million. November 2021 Company Presentation The company's non-invasive tests to diagnose skin conditions that are more effective than traditional biopsy-based diagnostic tests. The company's main test right now is called the DermTech Smart Sticker. This replaces a scalpel to remove the skin cells off the surface of a mole. The DermTech Smart Sticker provides an accurate, non-invasive test to detect melanoma. November Company Presentation Second Quarter Results: On August 8th, the company posted second quarter numbers. DermTech had a GAAP loss of 99 cents a share, slightly better than the consensus. Revenues rose nearly 36% on a year-over-year. However, revenues were only $4.23 million, and that was somewhat under expectations. The company's net loss for the quarter widened to $29.6 million compared with a loss of $17.1 million in 2Q2021. Assay revenue increased by over 40% to $4.15 million while contract revenue declined some 60% to just to $86,000. Billable sample volume grew 56% to 18,320 compared to the same period a year ago. The company also saw a 67% increase in unique ordering clinicians to approximately 2,390. Thanks to continued acceptance, DermTech Smart Sticker is now available to approximately 91 million covered lives. This breaks down as nearly 68 million for Medicare and Medicare Advantage and 23 million for commercial payers, which largely comes today from the Blue Shields of California, Illinois and Texas. The stock got hit when management took down their full year assay revenue estimate to $16 million to $19 million from $22 million to $26 million previously. The company has streamlined the laboratory processes, which reduced the per unit cost of the DermTech Smart Sticker by 28% sequentially to $177 per, but the product is also seeing a lower average selling price, or ASP, which is a key reason for the downward sales guidance revision. ASP was under pressure due to Medicare billing code edits, which are expected to be improved in the coming quarters. The company is pushing the launch of their direct-to-consumer offering "Luminate" that assesses skin cancer risk to the first half of 2023 to conserve costs. Analyst Commentary & Balance Sheet: Since second quarter results came out, four analyst firms including BTIG and Oppenheimer have reiterated Buy ratings. However, all four analyst firms significantly cut their price targets on DermTech. Price targets now proffered range from $14 to $24 a share. Prior to price target revisions, price targets from these four analyst firms was in the $19 to $48 range. Approximately one out of eight shares are currently held short. Numerous insiders have been frequent, but mostly small, sellers of the stock in 2022. They have sold approximately $500,000 worth of equity in aggregate so far this year. The last insider purchases of DMTK were in February of 2020. The company ended the second quarter of this year with just north of $175 million worth of cash and marketable securities on its balance sheet. Leadership believes this is sufficient capital to fund its current operating plan through the first quarter of 2024 Verdict: The current analyst consensus has the company losing nearly four bucks a share in FY2022 even as revenues advance over 50% to some $18 million. Next year, revenue growth is expected to accelerate with the company doing some $30 in sales in FY2023. However, losses are expected to only come down around 10%.
Analiz Makalesi • Aug 10

Earnings Release: Here's Why Analysts Cut Their DermTech, Inc. (NASDAQ:DMTK) Price Target To US$23.80

One of the biggest stories of last week was how DermTech, Inc. ( NASDAQ:DMTK ) shares plunged 33% in the week since its...
Seeking Alpha • Jun 13

DermTech: Approaching An All Or Nothing Moment

DermTech (DMTK) has transformative solutions that are more effective and accurate than traditional biopsy-based diagnostic approaches for detecting Skin Cancer. Commercialization of its proprietary SmartSticker solution has been slow, despite recent significant investments in the company’s salesforce. Although the company’s solutions have enormous potential and could drive the stock price significantly higher if successfully commercialized, recent management guidance for the next 12 months was soft. The future outcome for DMTK may be binary - either massive success driven by mass product adoption or a slow fade to oblivion based on failed commercialization.
Analiz Makalesi • Jun 04

We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Mar 31

DermTech - Taking A Second Look At The Growth Thesis

DMTK’s SmartSticker solution is proprietary and has been shown to be more effective and accurate than traditional biopsy-based diagnostic approaches, but the company must further commercialize this offering. DMTK has made significant sales, marketing and infrastructure investments over the past 6 months, which should drive 2022 to be a record financial year for the company. Investors should approach this opportunity with caution while collecting more data on DMTK’s ability to grow sales. The longer-term opportunity remains if DMTK can execute on its core growth strategies.
Seeking Alpha • Dec 23

DermTech: Adoption Headwinds And Earnings Misses

DMTK has a skin cancer diagnostics test in the market. The company has repeatedly missed earnings, and this time, they also lowered guidance. This sort of steady depletion of shareholder value does not look good for future investments.

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: DMTK.Q şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: DMTK.Q şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

DermTech Piyasaya Karşı Temettü Getirisi
DMTK.Q temettü verimi piyasa ile karşılaştırıldığında nasıldır?
SegmentTemettü Verimi
Şirket (DMTK.Q)n/a
Pazarın Alt %25'i (US)1.4%
Pazarın En İyi %25'i (US)4.3%
Sektör Ortalaması (Biotechs)2.4%
Analist tahmini (DMTK.Q) (3 yıla kadar)n/a

Önemli Temettü: DMTK.Q şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, DMTK.Q şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: DMTK.Q şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: DMTK.Q herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Güçlü temettü ödeyen şirketleri keşfedin

7D

1Y

7D

1Y

7D

1Y

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2025/07/23 22:57
Gün Sonu Hisse Fiyatı2025/07/23 00:00
Kazançlar2024/03/31
Yıllık Kazançlar2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

DermTech, Inc. 10 Bu analistlerden 0, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Sally YanchusBrookline Capital Markets
Mark MassaroBTIG
Alexander NowakCraig-Hallum Capital Group LLC